- Home
- GXAI vs ADIL Comparison
GXAI vs ADIL Comparison
Compare GXAI & ADIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GXAI | ADIL |
|---|---|---|
| Founded | 2021 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 7.8M |
| IPO Year | 2023 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GXAI | ADIL |
|---|---|---|
| Price | $1.10 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.50 |
| AVG Volume (30 Days) | 95.8K | ★ 350.5K |
| Earning Date | 11-13-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $694,278.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 23205.74 | N/A |
| 52 Week Low | $1.00 | $0.22 |
| 52 Week High | $5.10 | $1.30 |
Technical Indicators
Market Signals| Indicator | GXAI | ADIL |
|---|---|---|
| Relative Strength Index (RSI) | 34.38 | 32.77 |
| Support Level | $1.17 | $0.30 |
| Resistance Level | $1.30 | $0.32 |
| Average True Range (ATR) | 0.07 | 0.02 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 7.41 | 1.31 |
Price Performance
Historical ComparisonAbout GXAI Gaxos.ai Inc.
Gaxos.AI Inc is revolutionizing the way humans interact with artificial intelligence. The company offers applications related to mental and physical well-being, coaching, and gaming. The group is committed to tackling contemporary challenges such as how to live healthier and how to live longer. In addition to offering human-centered solutions, the company uses empathetic and AI technologies.
About ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.